Literature DB >> 2938737

Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.

M Sensi, L Grazioli, G Parmiani.   

Abstract

We have previously shown that YC8, a Moloney virus-induced BALB/c lymphoma, is susceptible to lysis by BALB/c anti-DBA/2 effector cells. To further evaluate the relationship between non-H-2 antigens of DBA/2 background and tumor-associated determinants, we investigated the pattern of cytotoxic and proliferative responses induced in BALB/c mice by immunization with YC8 lymphoma. Spleen cells from tumor-immunized animals were restimulated in vitro with YC8 cells and tested for cytotoxicity on target cells of different strains and haplotypes. Cytotoxicity was observed only against YC8, DBA/2 blasts, and P815 (a DBA/2 mastocytoma). BALB/c anti-YC8 effectors were equally blocked by unlabeled YC8 and P815 cells when assayed on YC8 labeled targets. A clonal analysis, however, revealed the existence of at least two types of effectors, one lytic for both P815 and YC8 cells, the other lytic for YC8 cells only. BALB/c anti-YC8 cells proliferate when stimulated both with YC8 and DBA/2 cells in the presence of accessory cells. When tested in an adoptive transfer assay, anti-YC8 cells given i.v. cured 100% of i.v. and 75% of i.p. tumor-injected mice, respectively. When given i.p. anti-YC8 effectors cured 100% of i.p. tumor-injected animals. These results confirm the expression of non-H-2, DBA/2-like antigens on the BALB/c lymphoma YC8 and reveal the presence of additional tumor-associated determinants; both sets of antigens may induce a cellular immune response and elicit immune lymphocytes which can eradicate YC8 cells in an adoptive immunotherapy assay.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938737     DOI: 10.1007/bf00199362

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

2.  Original H-2d and alien H-2k-like antigens of a BALB/c fibrosarcoma as defined by in vitro and in vivo studies of cell-mediated immunity.

Authors:  M Sensi; G Carbone; G Parmiani
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

3.  Tumor antigens as inappropriately expressed normal alloantigens.

Authors:  J H Russell; L C Ginns; G Terres; H N Eisen
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

4.  Studies on the nature of the cell surface antigen reacting with cytolytic T lymphocytes in murine oncornavirus-induced tumors.

Authors:  E Gomard; J P Levy; F Plata; Y Henin; V Duprez; A Bismuth; T Reme
Journal:  Eur J Immunol       Date:  1978-04       Impact factor: 5.532

5.  Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.

Authors:  G Parmiani; M L Sensi; G Carbone; M Colombo; M Pierotti; D Ballinari; J Hilgers; J Hilkens
Journal:  Int J Cancer       Date:  1982-03-15       Impact factor: 7.396

6.  Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.

Authors:  M P Colombo; M Parenza; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Multiple tumour-specific antigens expressed on a single tumour cell.

Authors:  R D Wortzel; C Philipps; H Schreiber
Journal:  Nature       Date:  1983 Jul 14-20       Impact factor: 49.962

8.  Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays.

Authors:  B M Vose; W White
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.

Authors:  M P Colombo; I Arioli; G Parmiani
Journal:  Int J Cancer       Date:  1984-12-15       Impact factor: 7.396

10.  Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.

Authors:  E Fernandez-Cruz; B A Woda; J D Feldman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.